Gene expression analysis identifies a genetic signature potentially associated with response to α-IFN in chronic phase CML patients

Leukemia Research

Volumn 31, Issue 7, 2007, Pages 931-938

  Hagberg, Anette ^a   Olsson Strömberg, Ulla ^a   Wickenberg Bolin, Ulrika ^a   Göransson, Hanna ^b   Isaksson, Anders ^a   Bengtsson, Mats ^a   Höglund, Martin ^a   Simonsson, Bengt ^a   Barbany, Gisela ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

CEBP; Chronic myeloid leukemia; Drug response; Gene expression profiling; Interferon; Microarray; RNASE2

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CYTARABINE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 34249808519     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.11.015     Document Type: Article

References (37)

1. Hehlmann R., Heimpel H., Hasford J., Kolb H.J., Pralle H., Hossfeld D.K., et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukaemia. The German CML Study Group. Blood 84 (1994) 4064-4077
2. Baccarani M., Rosti G., de Vivo A., Bonifazi F., Russo D., Martinelli G., et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 99 (2002) 1527-1535
3. Hasford J., Ansari H., Pfirrmann M., and Hehlmann R. Analysis and validation of prognostic factors for CML. German CML Study Group. Bone Marrow Transplant 17 Suppl. 3 (1996) S49-S54
4. Barbany G., Hoglund M., and Simonsson B. Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N Engl J Med 347 (2002) 539-540
5. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003) 1423-1432
6. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99 (2002) 3472-3475
7. Cortes J.E., O'Brien S.M., Giles F., Alvarez R.H., Talpaz M., and Kantarjian H.M. Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am 18 3 (2004) 619-639
8. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 (1999) 531-537
9. Haferlach T., Kohlmann A., Schnittger S., Dugas M., Hiddemann W., Kern W., et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106 (2005) 1189-1198
10. Yeoh E.J., Ross M.E., Shurtleff S.A., Williams W.K., Patel D., Mahfouz R., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1 (2002) 133-143
11. Shipp M.A., Ross K.N., Tamayo P., Weng A.P., Kutok J.L., Aguiar R.C., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8 (2002) 68-74
12. Korenberg M.J. Prediction of treatment response using gene expression profiles. J Proteome Res 1 (2002) 55-61
13. Chiaretti S., Li X., Gentleman R., Vitale A., Vignetti M., Mandelli F., et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 103 (2004) 2771-2778
14. Bohen S.P., Troyanskaya O.G., Alter O., Warnke R., Botstein D., Brown P.O., et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 100 (2003) 1926-1930
15. Kaneta Y., Kagami Y., Katagiri T., Tsunoda T., Jin-nai I., Taguchi H., et al. Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res 93 (2002) 849-856
16. McLean L.A., Gathmann I., Capdeville R., Polymeropoulos M.H., and Dressman M. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 10 (2004) 155-165
17. Villuendas R., Steegmann J.L., Pollan M., Tracey L., Granda A., Fernandez-Ruiz E., et al. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 20 (2006) 1047-1054
18. Crossman L.C., Mori M., Hsieh Y.C., Lange T., Paschka P., Harrington C.A., et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 90 (2005) 459-464
19. Simonsson B., Öberg G., Björeman M., Björkholm M., Carneskog J., Gahrton G., et al. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term folloe-up. Acta Haematol 113 (2005) 155-162
20. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia-a Europe Against Cancer program. Leukemia 17 (2003) 2318-2357
21. Cross N.C., Feng L., Chase A., Bungey J., Hughes T.P., and Goldman J.M. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82 (1993) 1929-1936
22. Hochhaus A., Lin F., Reiter A., Skladny H., Mason P.J., van Rhee F., et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 87 (1996) 1549-1555
23. Barbany G., Hagberg A., Olsson-Stromberg U., Simonsson B., Syvanen A.C., and Landegren U. Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem 46 (2000) 913-920
24. Baccarani M., Saglio G., Goldman J.M., Hochhaus A., Simonsson B., Appelbaum F., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
25. Fryknas M., Wickenberg-Bolin U., Goransson H., Gustafsson M.G., Foukakis T., Lee J.J., et al. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol 27 (2006) 211-220
26. Yang Y.H., Dudoit S., Luu P., Lin D.M., Peng V., Ngai J., et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30 (2002) e15
27. Sturn A., Quackenbush J., and Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 18 (2002) 207-208
28. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
29. Thorn I., Olsson-Stromberg U., Ohlsen C., Jonsson A.M., Klangby U., Simonsson B., et al. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. Haematologica 90 (2005) 1471-1476
30. Ohmine K., Ota J., Ueda M., Ueno S., Yoshida K., Yamashita Y., et al. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoetic stem cells. Oncogene 20 (2001) 8249-8257
31. Kronenwett R., Butterweck U., Steidl U., Kliszewski S., Neumann F., Bork S., et al. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene 24 (2005) 5313-5324
32. Zheng C., Li L., Haak M., Brors B., Frank O., Giehl M., et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 20 (2006) 1-7
33. Yong A.S., Szydlo R.M., Goldman J.M., Apperley J.F., and Melo J.V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 107 (2006) 205-212
34. Scott L.M., Civin C.I., Rorth P., and Friedman A.D. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 80 (1992) 1725-1735
35. Perrotti D., Cesi V., Trotta R., Guerzoni C., Santilli G., Campbell K., et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 30 (2002) 48-58
36. Guerzoni C., Bardini M., Mariani S.A., Ferrari-Amorotti G., Neviani P., Panno M.L., et al. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood 107 (2006) 4080-4089
37. Nowicki M.O., Pawlowski P., Fischer T., Hess G., Pawlowski T., and Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene 22 (2003) 3952-3963